Skip to contentD
DiaMedica Therapeutics Inc.
D
DMACDiaMedica Therapeutics Inc. Released Aug 12, 2025, after the close
10-Q filed Aug 12, 2025, 43 days after period end · 0001437749-25-026207
Q2 2025 · 10-Q
Revenue—
Net Income-$7.70M-$7.70MN/M vs Q2 2024N/M vs Q1 2025 EPS, diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR
—
Operating Income-$8,007,000N/M Operating Cash Flowderived-$7,598,000N/M Free Cash Flowderived-$7,604,000N/M ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end
+15.4% from the close of Aug 12, 2025 to the close of Aug 13, 2025, the first after the release.
after the close$5.20$6.00 Jul 22Aug 12Sep 4